Taysha Gene Therapies (TSHA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.62, -2.95% vs the prior close of $3.73.
- Volume 2.75M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TSHA dips 2.9% to $3.62. Closed at $3.62, -2.95% vs the prior close of $3.73. Day range $3.60–$3.74, opened at $3.73.
TSHA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TSHA dips 2.9% to $3.62
- Closed at $3.62, -2.95% vs the prior close of $3.73. Day range $3.60–$3.74, opened at $3.73.
- Volume was 2.75M shares, 0.8x its 50-day average of 3.57M.
- Price is -31.2% vs its 50-day average ($5.26) and -32.7% vs its 200-day average ($5.38).
- 52-week range $3.45–$7.30; today's close sits at 4% of that range, 50.4% below the 52-week high.
Oct 15, 2026 — TSHA jumps 6.3% to $3.73
- Closed at $3.73, +6.27% vs the prior close of $3.51. Day range $3.50–$3.79, opened at $3.53.
- Volume was 4.69M shares, 1.3x its 50-day average of 3.52M.
- Price is -29.8% vs its 50-day average ($5.31) and -30.7% vs its 200-day average ($5.39).
- 52-week range $3.45–$7.30; today's close sits at 7% of that range, 48.9% below the 52-week high.
Oct 14, 2026 — TSHA dips 2.0% to $3.51, a 52-week low, 3 down days in a row
- Closed at $3.51, -1.96% vs the prior close of $3.58. Day range $3.45–$3.71, opened at $3.51.
- Volume was 4.34M shares, 1.2x its 50-day average of 3.51M.
- Price is -34.6% vs its 50-day average ($5.37) and -34.9% vs its 200-day average ($5.40).
- 52-week range $3.45–$7.30; today's close sits at 1% of that range, 51.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — TSHA slides 13.5% to $3.58, a 52-week low
- Closed at $3.58, -13.53% vs the prior close of $4.14. Day range $3.55–$4.13, opened at $4.09.
- Volume was 6.12M shares, 1.8x its 50-day average of 3.42M.
- Price is -34.0% vs its 50-day average ($5.42) and -33.8% vs its 200-day average ($5.41).
- 52-week range $3.55–$7.30; today's close sits at 1% of that range, 51.0% below the 52-week high.
Oct 12, 2026 — TSHA slides 7.8% to $4.14, a 6-month low
- Closed at $4.14, -7.80% vs the prior close of $4.49. Day range $4.12–$4.56, opened at $4.46.
- Volume was 4.21M shares, 1.2x its 50-day average of 3.38M.
- Price is -24.3% vs its 50-day average ($5.47) and -23.6% vs its 200-day average ($5.42).
- 52-week range $3.69–$7.30; today's close sits at 12% of that range, 43.3% below the 52-week high.
Oct 9, 2026 — TSHA rises 1.4% to $4.49
- Closed at $4.49, +1.35% vs the prior close of $4.43. Day range $4.36–$4.57, opened at $4.42.
- Volume was 5.38M shares, 1.6x its 50-day average of 3.34M.
- Price is -18.4% vs its 50-day average ($5.50) and -17.3% vs its 200-day average ($5.43).
- 52-week range $3.69–$7.30; today's close sits at 22% of that range, 38.5% below the 52-week high.
Oct 8, 2026 — TSHA ends flat (+0.0%) to $4.43
- Closed at $4.43, +0.00% vs the prior close of $4.43. Day range $4.32–$4.45, opened at $4.37.
- Volume was 3.91M shares, 1.2x its 50-day average of 3.32M.
- Price is -19.9% vs its 50-day average ($5.53) and -18.5% vs its 200-day average ($5.43).
- 52-week range $3.69–$7.30; today's close sits at 20% of that range, 39.3% below the 52-week high.
Oct 7, 2026 — TSHA rises 0.9% to $4.43
- Closed at $4.43, +0.91% vs the prior close of $4.39. Day range $4.26–$4.46, opened at $4.33.
- Volume was 3.91M shares, 1.2x its 50-day average of 3.29M.
- Price is -20.2% vs its 50-day average ($5.55) and -18.5% vs its 200-day average ($5.44).
- 52-week range $3.69–$7.30; today's close sits at 20% of that range, 39.3% below the 52-week high.
Oct 6, 2026 — TSHA dips 2.2% to $4.39, a 6-month low, 6 down days in a row
- Closed at $4.39, -2.23% vs the prior close of $4.49. Day range $4.26–$4.57, opened at $4.51.
- Volume was 4.83M shares, 1.5x its 50-day average of 3.24M.
- Price is -21.2% vs its 50-day average ($5.57) and -19.4% vs its 200-day average ($5.44).
- 52-week range $3.69–$7.30; today's close sits at 19% of that range, 39.9% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — TSHA slides 3.0% to $4.49, a 3-month low, 5 down days in a row
- Closed at $4.49, -3.02% vs the prior close of $4.63. Day range $4.37–$4.64, opened at $4.64.
- Volume was 4.97M shares, 1.6x its 50-day average of 3.18M.
- Price is -19.8% vs its 50-day average ($5.60) and -17.6% vs its 200-day average ($5.45).
- 52-week range $3.69–$7.30; today's close sits at 22% of that range, 38.5% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — TSHA dips 2.3% to $4.63, a 3-month low, 4 down days in a row
- Closed at $4.63, -2.32% vs the prior close of $4.74. Day range $4.63–$4.86, opened at $4.80.
- Volume was 2.99M shares, 0.9x its 50-day average of 3.17M.
- Price is -17.6% vs its 50-day average ($5.62) and -15.1% vs its 200-day average ($5.46).
- 52-week range $3.69–$7.30; today's close sits at 26% of that range, 36.6% below the 52-week high.
- That makes 4 straight losses.
TSHA latest news & SEC filings
Every SEC filing by or about TSHA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $1.99M) (-100.0% vs Jun 30, 2025)
- Net income: -$46.64M (prior year -$26.88M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.13 (prior year -$0.09) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Nagendran Sukumar sold 200,000 shares at $6.24 (≈$1.25M) on Jul 10, 2026
- Nagendran Sukumar sold 200,000 shares at $6.24 (≈$1.25M) on Jul 10, 2026
- Nagendran Sukumar sold 200,000 shares at $6.24 (≈$1.25M) on Jul 10, 2026
- Nagendran Sukumar sold 200,000 shares at $6.24 (≈$1.25M) on Jul 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jun 25, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 24, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade TSHA
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 19, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.34% (largest 13.5%). That is a volatile stock.
- Liquidity: about 4.46M shares (≈$16.15M) trade per day on average.
- 52-week position: $3.62 vs a range of $3.45–$7.30 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Sukumar Nagendran sold 200,000 shares on Jul 10, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jun 25, 2026.
- Share count: 325.83M shares outstanding (Aug 11, 2026), +19.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
TSHA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.73 | 3.74 | 3.60 | 3.62 | 2.75M |
| Oct 15, 2026 | 3.53 | 3.79 | 3.50 | 3.73 | 4.69M |
| Oct 14, 2026 | 3.51 | 3.71 | 3.45 | 3.51 | 4.34M |
| Oct 13, 2026 | 4.09 | 4.13 | 3.55 | 3.58 | 6.12M |
| Oct 12, 2026 | 4.46 | 4.56 | 4.12 | 4.14 | 4.21M |
| Oct 9, 2026 | 4.42 | 4.57 | 4.36 | 4.49 | 5.38M |
| Oct 8, 2026 | 4.37 | 4.45 | 4.32 | 4.43 | 3.91M |
| Oct 7, 2026 | 4.33 | 4.46 | 4.26 | 4.43 | 3.91M |
| Oct 6, 2026 | 4.51 | 4.57 | 4.26 | 4.39 | 4.83M |
| Oct 5, 2026 | 4.64 | 4.64 | 4.37 | 4.49 | 4.97M |
| Oct 2, 2026 | 4.80 | 4.86 | 4.63 | 4.63 | 2.99M |
| Oct 1, 2026 | 4.86 | 4.93 | 4.73 | 4.74 | 3.85M |
| Sep 30, 2026 | 5.03 | 5.03 | 4.82 | 4.87 | 3.90M |
| Sep 29, 2026 | 4.97 | 5.03 | 4.80 | 4.99 | 6.57M |
| Sep 28, 2026 | 4.64 | 5.05 | 4.56 | 4.99 | 6.26M |
| Sep 25, 2026 | 4.88 | 4.88 | 4.66 | 4.67 | 4.66M |
| Sep 24, 2026 | 4.88 | 4.90 | 4.66 | 4.79 | 6.40M |
| Sep 23, 2026 | 5.11 | 5.14 | 4.88 | 4.91 | 5.51M |
| Sep 22, 2026 | 5.11 | 5.22 | 5.08 | 5.16 | 2.31M |
| Sep 21, 2026 | 5.07 | 5.12 | 4.99 | 5.04 | 1.68M |
About Taysha Gene Therapies
Taysha Gene Therapies (TSHA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in DALLAS, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1806310.
TSHA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Phillip B. Donenberg | Director | Jun 2, 2026 |
| Alison S Long | Director | Jun 2, 2026 |
| Sukumar Nagendran | President and Head of R&D | Jul 10, 2026 |
| Sean P. Nolan | Chief Executive Officer | Jan 27, 2026 |
| Laura Sepp-Lorenzino | Director | Jun 2, 2026 |
| John A Iii Stalfort | Director | Jun 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kamran Alam | CHIEF FINANCIAL OFFICER | Feb 6, 2026 |
| Sukumar Nagendran | President and Head of R&D | Jul 10, 2026 |
| Sean P. Nolan | Chief Executive Officer | Jan 27, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $6.24 |
| Jul 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $6.24 |
| Jul 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $6.24 |
| Jul 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $6.24 |
| Apr 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $4.46 |
| Apr 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $4.46 |
| Apr 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $4.46 |
| Apr 10, 2026 | Sukumar Nagendran | Sale | 200,000 | $4.46 |
| Feb 4, 2026 | Kamran Alam | Sale | 1,655 | $4.52 |
| Feb 4, 2026 | Kamran Alam | Sale | 1,655 | $4.52 |
| Feb 4, 2026 | Kamran Alam | Sale | 1,655 | $4.52 |
| Feb 4, 2026 | Kamran Alam | Sale | 1,655 | $4.52 |
| Jan 26, 2026 | Sukumar Nagendran | Sale | 26,918 | $4.61 |
| Jan 26, 2026 | Sukumar Nagendran | Sale | 26,918 | $4.61 |
| Jan 26, 2026 | Sukumar Nagendran | Sale | 26,918 | $4.61 |
TSHA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $9.77M | $-109.00M | -0.34 | $-93.09M |
| Dec 31, 2024 | $8.33M | $-89.30M | -0.36 | $-81.22M |
| Dec 31, 2023 | $15.45M | $-111.57M | -0.96 | $-73.02M |
| Dec 31, 2022 | $2.50M | $-166.01M | -3.78 | $-88.39M |
| Dec 31, 2021 | — | $-174.52M | -4.64 | $-117.04M |
Latest balance sheet: total assets $470.43M, total liabilities $83.17M, cash $455.41M (as of Jun 30, 2026).
TSHA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $6.68 |
| May 6, 2026 | 8-K Item 2.02 (results) | $6.98 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $4.56 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $4.27 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $2.91 |
| May 15, 2025 | 8-K Item 2.02 (results) | $2.56 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $1.62 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $2.21 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| Jun 26, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TSHA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.